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It is becoming increasingly clear that the immune profile
of breast cancer patients is informative for patient prog-
nosis. Specifically, immune cells with suppressor or effec-
tor function have been shown to be valuable in the
prediction of patient course on an individual basis. Our
previous study has shown that patients with in vitro
HER2-reactive peripheral CD8+ T cells, high levels of cir-
culating plasmacytoid dendritic cells (pDCs) but low ratios
of Myeloid-Derived Suppressor Cells (MDSCs):pDCs and
Regulatory T cells (Tregs):pDCs experience a survival
advantage. In the present study we have tested T cell
responses to additional tumour associated antigens along
with an expanded panel of leukocyte phenotypes including
myeloid cells (9 different phenotypes including monocytes,
MDSCs, pDCs and monocyte-derived dendritic cells
(mDCs)), T cells (5 phenotypes including Tregs) and NK
cells in a cohort of 50 prospectively enrolled breast cancer
patients with early stage invasive ductal carcinoma. Addi-
tionally, we have performed an in vitro expansion of T
cells responding to peptides derived from the tumour-
associated antigens Survivin and MUC-1, as well as HER-2
to validate our previous results, and influenza peptides as
a positive biological control. To characterise the type of
the T cell response to these antigens, responding CD4+
and CD8+ cells were assessed for IFNg, TNF, IL-2, IL-5,
IL-10 and IL-17 production per cell by intracytoplasmic
flow cytometry, producing 6-cytokine T cell polyfunction-
ality data. Thus, this study sought to assess the relation-
ship between the distribution of peripheral blood myeloid
cells, T cells and NK cells and the presence or absence of
in vitro T cell responses to tumour-associated antigens in
breast cancer. Ongoing analyses will reveal associations
between the levels of different leukocyte populations with
T cell responses to tumour-associated antigens. Subse-
quent clinical follow-up will prospectively reveal associa-
tions of these factors with patient clinical course.
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